A Randomized Trial of Radical Cystectomy Versus Radical Cystectomy Plus Cisplatin, Vinblastine and Methotrexate Chemotherapy for Muscle Invasive Bladder Cancer
- 1 February 1996
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 155 (2), 495-500
- https://doi.org/10.1016/s0022-5347(01)66430-9
Abstract
Standard treatment for muscle invasive transitional cell cancer of the bladder is radical cystectomy. Despite careful staging, the majority of cancers with regional lymph node involvement and/or invasion to adjacent organs eventually recur. We investigated the benefit of chemotherapy with cisplatin, methotrexate and vinblastine (CMV) after radical cystectomy.A prospective trial was done in which patients were randomized after cystectomy to receive either 4 cycles of CMV chemotherapy or observation. At relapse, patients were treated with standard CMV chemotherapy for metastatic disease at our institution.Of 55 patients who entered this trial 1 was ineligible and in 4 it is too soon to be evaluated. Of the 50 evaluable patients 25 were randomized to receive adjuvant CMV chemotherapy and 25 were observed. In the CMV arm 12 (48%) and in the observation arm 5 (25%) never had recurrence. With a median followup of 62 months and no patient with less than 2 years of followup, the freedom from progression in the adjuvant chemotherapy group was superior to that in the observation group (median 37 versus 12 months, respectively, p = 0.01). Median survival in the adjuvant group was 63 months compared to 36 months for the observation group. Surprisingly, some cases with relapse could be salvaged with CMV chemotherapy, perhaps contributing to this lack of difference in overall survival (p = 0.32).Treatment with CMV chemotherapy after radical cystectomy is an acceptable approach in patients with stages p3b and p4N0 or N1 transitional cell carcinoma of the bladder. Further studies must be performed to determine whether these results can be extrapolated to patients with more limited disease (stages p2 and p3a) who are currently treated with radical cystectomy or definitive irradiation.Keywords
This publication has 15 references indexed in Scilit:
- CMV front-line chemotherapy in transitional bladder carcinomaAnnals of Oncology, 1993
- Advanced Bladder Cancer (Stages pT3b, pT4a, pN1 and pN2): Improved Survival after Radical Cystectomy and 3 Adjuvant Cycles of Chemotherapy. Results of a Controlled Prospective StudyJournal of Urology, 1992
- Initial Combination Chemotherapy with Cisplatin, Methotrexate and Vinblastine in Locally Advanced Transitional Cell Carcinoma—Response Rate and PitfallsBritish Journal of Urology, 1992
- Stage B (Urology, 1992
- Adjuvant Chemotherapy of Bladder Cancer: A Preliminary ReportJournal of Urology, 1988
- Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.Journal of Clinical Oncology, 1985
- High Dose, Short Course Preoperative Radiation Therapy and Immediate Single Stage Radical Cystectomy with Pelvic Node Dissection in the Management of Bladder CancerJournal of Urology, 1982
- Regional Lymph Node Metastasis From Bladder CancerJournal of Urology, 1981
- The Upper Limits of Hopeful Application of Radical Cystectomy for Vesical Carcinoma: Does Nodal Metastasis Always Indicate Incurability?Journal of Urology, 1973
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958